Progesterone receptor is a surrogate marker of estrogen receptor activity in breast cancer
and its utility in helping predict clinical outcome has been established using biochemical …

Estrogen receptor (ER) and progesterone receptor (PR) status in breast carcinomas are
considered validated predictive factors for selecting patients for antihormonal therapy …

Background An immunohistochemical (IHC) method is commonly used for determining
estrogen receptor (ER) and progesterone receptor (PR) status in breast cancer. However …

Estrogen receptor status in breast cancer is associated with response to hormonal therapy
and clinical outcome. The additional value of progesterone receptor (PR) has remained …

The biochemical assay for the oestrogen receptor has shown the clinical value of knowing
the concentration of the receptor within tissue. The immunohistochemical assay is rapidly …

OBJECTIVE: The authors investigated correlations of estrogen-receptor and progesterone-
receptor with conventional risk factors as well as histopathology in patients with primary …

Context.—Estrogen receptor and progesterone receptor status is assessed on all newly
diagnosed, invasive breast carcinomas and in recurrences to determine patient eligibility for …

Breast cancer is the predominant malignancy where oncologists use predictive markers
clinically to select treatment options, with steroid receptors having been used for many …

The assessment of steroid hormone receptors in resected breast carcinoma tissue is
currently the standard of practice. The traditional method for assessment of receptor status is …

The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most
important prognostic and predictive immunohistochemical markers in breast cancer. Breast …